Skip to main content
Premium Trial:

Request an Annual Quote

Abpro Licenses HER2-Targeteing Bispecific Antibody to Celltrion

NEW YORK – Abpro said on Wednesday that it has out-licensed commercialization rights for its HER2-targeted cancer therapy ABP 102 to the South Korean biopharmaceutical firm Celltrion.

Under the terms of the global partnership, Celltrion will pay Abpro up to $1.75 billion for the rights to commercialize ABP 102 worldwide. That amount includes an equity investment, potential development and commercialization milestone payments, and worldwide profit sharing. Once Abpro completes in vitro studies of ABP 102, Celltrion will take over the therapy's development.

Woburn, Massachusetts-based Abpro developed ABP 102, a bispecific antibody, as a treatment for HER2-positive cancers, including breast, gastric, and pancreatic cancers. 

"Abpro's ABP 102 molecule has shown preliminary data of better efficacy and less toxicity compared to other therapies treating the same indication," Sooyoung Lee, VP and head of new drug research at Celltrion, said in a statement. "We are confident this partnership will allow us to deliver the best possible care to patients suffering from HER2+ cancer."

Abpro used its DiversImmune and MultiMab platforms to develop the drug. The DiversImmune platform uses nano-immunology, next-generation sequencing, advanced engineering, and bioinformatics to generate therapies against difficult targets. MultiMab, meanwhile, uses dual-targeting antibodies to bind to both the tumor cell and T cell simultaneously, engaging the T cells to attack the cancer.